Cardiac muscle wasting in individuals with cancer cachexia

Aims Cachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with cancer manifest symptoms, such as fatigue, shortness of breath, and impaired exercise tolerance, which are clinical signs of chronic heart f...

Full description

Saved in:
Bibliographic Details
Published inESC Heart Failure Vol. 4; no. 4; pp. 458 - 467
Main Authors Barkhudaryan, Anush, Scherbakov, Nadja, Springer, Jochen, Doehner, Wolfram
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.11.2017
John Wiley and Sons Inc
Subjects
Adult
Aged
Aged, 80 and over
Anorexia
Body Mass Index
Cachexia - complications
Cachexia - epidemiology
Cachexia - metabolism
Cancer cachexia
Cancer therapies
Cardiac function
Chemotherapy
Drug therapy
Family medical history
Female
Fitness training programs
Germany - epidemiology
Heart
Heart Failure - epidemiology
Heart Failure - etiology
Heart Failure - metabolism
Heart weight
Humans
Laboratories
Lung cancer
Male
Medical prognosis
Middle Aged
Morbidity - trends
Muscle, Skeletal - metabolism
Muscle, Skeletal - physiopathology
Musculoskeletal system
Myocardium - metabolism
Neoplasms - complications
Neoplasms - epidemiology
Original
Original s
Pancreatic cancer
Pathology
Proteins
Pulmonary arteries
Quality of life
Retrospective Studies
Studies
Survival Rate - trends
Tumor necrosis factor-TNF
Weight loss
Young Adult
Cancer cachexia
Heart weight
Cardiac function
Weight loss
Online AccessGet full text
ISSN2055-5822
2055-5822
DOI10.1002/ehf2.12184

Cover

Abstract Aims Cachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with cancer manifest symptoms, such as fatigue, shortness of breath, and impaired exercise tolerance, which are clinical signs of chronic heart failure. The aim of this study was to evaluate cardiac muscle wasting in cancer individuals. Methods and results We retrospectively analysed 177 individuals who died of cancer, including 58 lung, 60 pancreatic, and 59 gastrointestinal (GI) cancers, and 42 cancer‐free controls who died of other, non‐cardiovascular reasons. Cancer cachexia (CC) was defined based on clinical and/or pathological diagnosis, body mass index (BMI) <20.0 kg/m2 and/or oedema‐free body weight loss of 5.0% during the previous year or less. The pathology reports were analysed for BMI, heart weight (HW), and left and right ventricular wall thicknesses (LVWT and RVWT, respectively). The analysis of clinical data included recording of biochemical parameters and medication data of study patients. CC was detected in 54 (30.5%) subjects. Individuals with CC had a significantly lower HW than non‐cachectic subjects (363.1 ± 86.2 vs. 447.0 ± 128.9 g, P < 0.001) and control group (412.9 ± 75.8 g, P < 0.05). BMI correlated with HW in cases with GI cancer (r = 0.44, P < 0.001), lung cancer (r = 0.53, P < 0.0001), and pancreatic cancer (r = 0.39, P < 0.01). Conclusions Body weight loss in individuals with lung, pancreatic, and GI cancers is accompanied by a decrease in HW. In patients with CC who receive cancer treatment, screening for cardiac muscle wasting may have clinical importance.
AbstractList AimsCachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with cancer manifest symptoms, such as fatigue, shortness of breath, and impaired exercise tolerance, which are clinical signs of chronic heart failure. The aim of this study was to evaluate cardiac muscle wasting in cancer individuals.Methods and resultsWe retrospectively analysed 177 individuals who died of cancer, including 58 lung, 60 pancreatic, and 59 gastrointestinal (GI) cancers, and 42 cancer‐free controls who died of other, non‐cardiovascular reasons. Cancer cachexia (CC) was defined based on clinical and/or pathological diagnosis, body mass index (BMI) <20.0 kg/m2 and/or oedema‐free body weight loss of 5.0% during the previous year or less. The pathology reports were analysed for BMI, heart weight (HW), and left and right ventricular wall thicknesses (LVWT and RVWT, respectively). The analysis of clinical data included recording of biochemical parameters and medication data of study patients. CC was detected in 54 (30.5%) subjects. Individuals with CC had a significantly lower HW than non‐cachectic subjects (363.1 ± 86.2 vs. 447.0 ± 128.9 g, P < 0.001) and control group (412.9 ± 75.8 g, P < 0.05). BMI correlated with HW in cases with GI cancer (r = 0.44, P < 0.001), lung cancer (r = 0.53, P < 0.0001), and pancreatic cancer (r = 0.39, P < 0.01).ConclusionsBody weight loss in individuals with lung, pancreatic, and GI cancers is accompanied by a decrease in HW. In patients with CC who receive cancer treatment, screening for cardiac muscle wasting may have clinical importance.
Cachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with cancer manifest symptoms, such as fatigue, shortness of breath, and impaired exercise tolerance, which are clinical signs of chronic heart failure. The aim of this study was to evaluate cardiac muscle wasting in cancer individuals. We retrospectively analysed 177 individuals who died of cancer, including 58 lung, 60 pancreatic, and 59 gastrointestinal (GI) cancers, and 42 cancer-free controls who died of other, non-cardiovascular reasons. Cancer cachexia (CC) was defined based on clinical and/or pathological diagnosis, body mass index (BMI) <20.0 kg/m and/or oedema-free body weight loss of 5.0% during the previous year or less. The pathology reports were analysed for BMI, heart weight (HW), and left and right ventricular wall thicknesses (LVWT and RVWT, respectively). The analysis of clinical data included recording of biochemical parameters and medication data of study patients. CC was detected in 54 (30.5%) subjects. Individuals with CC had a significantly lower HW than non-cachectic subjects (363.1 ± 86.2 vs. 447.0 ± 128.9 g, P < 0.001) and control group (412.9 ± 75.8 g, P < 0.05). BMI correlated with HW in cases with GI cancer (r = 0.44, P < 0.001), lung cancer (r = 0.53, P < 0.0001), and pancreatic cancer (r = 0.39, P < 0.01). Body weight loss in individuals with lung, pancreatic, and GI cancers is accompanied by a decrease in HW. In patients with CC who receive cancer treatment, screening for cardiac muscle wasting may have clinical importance.
Cachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with cancer manifest symptoms, such as fatigue, shortness of breath, and impaired exercise tolerance, which are clinical signs of chronic heart failure. The aim of this study was to evaluate cardiac muscle wasting in cancer individuals.AIMSCachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with cancer manifest symptoms, such as fatigue, shortness of breath, and impaired exercise tolerance, which are clinical signs of chronic heart failure. The aim of this study was to evaluate cardiac muscle wasting in cancer individuals.We retrospectively analysed 177 individuals who died of cancer, including 58 lung, 60 pancreatic, and 59 gastrointestinal (GI) cancers, and 42 cancer-free controls who died of other, non-cardiovascular reasons. Cancer cachexia (CC) was defined based on clinical and/or pathological diagnosis, body mass index (BMI) <20.0 kg/m2 and/or oedema-free body weight loss of 5.0% during the previous year or less. The pathology reports were analysed for BMI, heart weight (HW), and left and right ventricular wall thicknesses (LVWT and RVWT, respectively). The analysis of clinical data included recording of biochemical parameters and medication data of study patients. CC was detected in 54 (30.5%) subjects. Individuals with CC had a significantly lower HW than non-cachectic subjects (363.1 ± 86.2 vs. 447.0 ± 128.9 g, P < 0.001) and control group (412.9 ± 75.8 g, P < 0.05). BMI correlated with HW in cases with GI cancer (r = 0.44, P < 0.001), lung cancer (r = 0.53, P < 0.0001), and pancreatic cancer (r = 0.39, P < 0.01).METHODS AND RESULTSWe retrospectively analysed 177 individuals who died of cancer, including 58 lung, 60 pancreatic, and 59 gastrointestinal (GI) cancers, and 42 cancer-free controls who died of other, non-cardiovascular reasons. Cancer cachexia (CC) was defined based on clinical and/or pathological diagnosis, body mass index (BMI) <20.0 kg/m2 and/or oedema-free body weight loss of 5.0% during the previous year or less. The pathology reports were analysed for BMI, heart weight (HW), and left and right ventricular wall thicknesses (LVWT and RVWT, respectively). The analysis of clinical data included recording of biochemical parameters and medication data of study patients. CC was detected in 54 (30.5%) subjects. Individuals with CC had a significantly lower HW than non-cachectic subjects (363.1 ± 86.2 vs. 447.0 ± 128.9 g, P < 0.001) and control group (412.9 ± 75.8 g, P < 0.05). BMI correlated with HW in cases with GI cancer (r = 0.44, P < 0.001), lung cancer (r = 0.53, P < 0.0001), and pancreatic cancer (r = 0.39, P < 0.01).Body weight loss in individuals with lung, pancreatic, and GI cancers is accompanied by a decrease in HW. In patients with CC who receive cancer treatment, screening for cardiac muscle wasting may have clinical importance.CONCLUSIONSBody weight loss in individuals with lung, pancreatic, and GI cancers is accompanied by a decrease in HW. In patients with CC who receive cancer treatment, screening for cardiac muscle wasting may have clinical importance.
Aims Cachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with cancer manifest symptoms, such as fatigue, shortness of breath, and impaired exercise tolerance, which are clinical signs of chronic heart failure. The aim of this study was to evaluate cardiac muscle wasting in cancer individuals. Methods and results We retrospectively analysed 177 individuals who died of cancer, including 58 lung, 60 pancreatic, and 59 gastrointestinal (GI) cancers, and 42 cancer‐free controls who died of other, non‐cardiovascular reasons. Cancer cachexia (CC) was defined based on clinical and/or pathological diagnosis, body mass index (BMI) <20.0 kg/m2 and/or oedema‐free body weight loss of 5.0% during the previous year or less. The pathology reports were analysed for BMI, heart weight (HW), and left and right ventricular wall thicknesses (LVWT and RVWT, respectively). The analysis of clinical data included recording of biochemical parameters and medication data of study patients. CC was detected in 54 (30.5%) subjects. Individuals with CC had a significantly lower HW than non‐cachectic subjects (363.1 ± 86.2 vs. 447.0 ± 128.9 g, P < 0.001) and control group (412.9 ± 75.8 g, P < 0.05). BMI correlated with HW in cases with GI cancer (r = 0.44, P < 0.001), lung cancer (r = 0.53, P < 0.0001), and pancreatic cancer (r = 0.39, P < 0.01). Conclusions Body weight loss in individuals with lung, pancreatic, and GI cancers is accompanied by a decrease in HW. In patients with CC who receive cancer treatment, screening for cardiac muscle wasting may have clinical importance.
Author Doehner, Wolfram
Barkhudaryan, Anush
Springer, Jochen
Scherbakov, Nadja
AuthorAffiliation 3 German Centre for Cardiovascular Research (DZHK) Berlin Germany
1 Clinic of General and Invasive Cardiology University Clinical Hospital No. 1 Yerevan Armenia
4 Institute of Innovative Clinical Trials, Department of Cardiology and Pneumology University Medical Centre Göttingen (UMG) Göttingen Germany
5 Department of Cardiology and Berlin‐Brandenburg Center for Regenerative Therapies, Campus Virchow Charite Universitätsmedizin Berlin Berlin Germany
2 Center for Stroke Research Berlin Charite Universitätsmedizin Berlin Berlin Germany
AuthorAffiliation_xml – name: 3 German Centre for Cardiovascular Research (DZHK) Berlin Germany
– name: 2 Center for Stroke Research Berlin Charite Universitätsmedizin Berlin Berlin Germany
– name: 4 Institute of Innovative Clinical Trials, Department of Cardiology and Pneumology University Medical Centre Göttingen (UMG) Göttingen Germany
– name: 5 Department of Cardiology and Berlin‐Brandenburg Center for Regenerative Therapies, Campus Virchow Charite Universitätsmedizin Berlin Berlin Germany
– name: 1 Clinic of General and Invasive Cardiology University Clinical Hospital No. 1 Yerevan Armenia
Author_xml – sequence: 1
  givenname: Anush
  surname: Barkhudaryan
  fullname: Barkhudaryan, Anush
  organization: University Clinical Hospital No. 1
– sequence: 2
  givenname: Nadja
  surname: Scherbakov
  fullname: Scherbakov, Nadja
  organization: German Centre for Cardiovascular Research (DZHK)
– sequence: 3
  givenname: Jochen
  surname: Springer
  fullname: Springer, Jochen
  organization: University Medical Centre Göttingen (UMG)
– sequence: 4
  givenname: Wolfram
  surname: Doehner
  fullname: Doehner, Wolfram
  email: wolfram.doehner@charite.de
  organization: Charite Universitätsmedizin Berlin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29154433$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtLAzEUhYNUbH1s_AEy4EaE0Tzn4UKQ4gsKbnQdbjO3NmWaqcmM1X9valVURAjcwP3O4SRnm_Rc45CQfUZPGKX8FKcTfsI4K-QGGXCqVKoKznvf7n2yF8KMUspUxhSXW6TPS6akFGJAzobgKwsmmXfB1JgsIbTWPSbWxVPZZ1t1UIdkadtpYsAZ9HGYKb5Y2CWbk7jDvY-5Qx6uLu-HN-no7vp2eDFKjcwzmQpRSVMCZ8BLQA5ADRpFY7CimAgcM8jzscQqx0IylktqpMlpVQiuxhJAiR1yvvZddOM5VgZd66HWC2_n4F91A1b_3Dg71Y_Ns1ZZqVguosHRh4FvnjoMrZ7bYLCuwWHTBc3KLJOyoKKM6OEvdNZ03sXnac5LymJqmUfq4Huiryif3xoBugaMb0LwONHGttDaZhXQ1ppRvSpPr8rT7-VFyfEvyafrnzBbw0tb4-s_pL68ueJrzRvT_afs
CitedBy_id crossref_primary_10_3390_ijerph17134904
crossref_primary_10_14814_phy2_70044
crossref_primary_10_1016_j_tranon_2019_12_006
crossref_primary_10_3389_fimmu_2022_947267
crossref_primary_10_1155_2023_1179848
crossref_primary_10_18632_oncotarget_27748
crossref_primary_10_3390_nu14142824
crossref_primary_10_1002_cam4_6388
crossref_primary_10_15420_cfr_2018_32_2
crossref_primary_10_1016_j_beem_2021_101598
crossref_primary_10_1016_j_biopha_2023_115117
crossref_primary_10_1055_a_2337_4025
crossref_primary_10_1097_SPC_0000000000000456
crossref_primary_10_1016_j_heliyon_2024_e25562
crossref_primary_10_3390_cells11061040
crossref_primary_10_1002_ejhf_2840
crossref_primary_10_3390_cells11060990
crossref_primary_10_1136_bmj_2024_080040
crossref_primary_10_1002_ehf2_12555
crossref_primary_10_1093_dote_doad062
crossref_primary_10_1002_ehf2_12356
crossref_primary_10_3390_cimb46120797
crossref_primary_10_1016_j_celrep_2022_111934
crossref_primary_10_1002_jcsm_13267
crossref_primary_10_1002_jcsm_12694
crossref_primary_10_1007_s43440_020_00179_y
crossref_primary_10_1002_jcsm_12528
crossref_primary_10_1242_dmm_038240
crossref_primary_10_3389_fcell_2022_960341
crossref_primary_10_1093_eurheartj_suz241
crossref_primary_10_1002_jcsm_13217
crossref_primary_10_1002_jcsm_12402
crossref_primary_10_1093_eurheartj_ehae438
crossref_primary_10_3390_cancers13040850
crossref_primary_10_3390_cancers13102303
crossref_primary_10_1016_j_lfs_2020_118392
crossref_primary_10_1002_ejhf_2071
crossref_primary_10_1016_j_molmed_2018_06_002
crossref_primary_10_1007_s00108_020_00887_w
crossref_primary_10_1200_JCO_20_03465
crossref_primary_10_1016_j_clnu_2020_02_017
crossref_primary_10_1152_ajpheart_00795_2023
crossref_primary_10_1007_s10555_020_09869_8
crossref_primary_10_1002_ejhf_1665
crossref_primary_10_1016_j_celrep_2019_04_107
crossref_primary_10_1016_j_lfs_2024_123170
crossref_primary_10_15406_ijcam_2020_13_00514
crossref_primary_10_3390_cancers16030542
crossref_primary_10_1111_avj_13039
crossref_primary_10_1038_s41574_018_0123_0
crossref_primary_10_1002_jcsm_13009
crossref_primary_10_4081_cardio_2024_58
crossref_primary_10_1253_circj_CJ_23_0838
crossref_primary_10_3390_cells11121931
crossref_primary_10_1016_j_crad_2019_11_003
crossref_primary_10_1038_s41598_018_23669_9
crossref_primary_10_1002_ejhf_1252
crossref_primary_10_1002_ehf2_13069
crossref_primary_10_1038_s41569_022_00806_6
crossref_primary_10_1371_journal_pone_0226440
crossref_primary_10_33920_med_01_2306_01
crossref_primary_10_1002_mco2_164
crossref_primary_10_1007_s00395_024_01079_5
crossref_primary_10_1113_JP276746
crossref_primary_10_3390_antiox10081299
crossref_primary_10_1016_j_jacc_2023_02_039
crossref_primary_10_1080_14737140_2021_1927720
crossref_primary_10_1002_rco2_34
crossref_primary_10_36150_2499_6564_N638
crossref_primary_10_1152_ajpcell_00424_2022
crossref_primary_10_1002_rco2_30
crossref_primary_10_3389_fcvm_2022_929259
crossref_primary_10_1038_s41389_020_00288_6
crossref_primary_10_1002_ejhf_2059
crossref_primary_10_1016_j_autneu_2023_103136
crossref_primary_10_1097_MCO_0000000000000951
crossref_primary_10_1002_ehf2_12389
crossref_primary_10_1007_s12012_022_09727_9
crossref_primary_10_1002_jcsm_12388
crossref_primary_10_1152_japplphysiol_00829_2018
crossref_primary_10_1002_ehf2_12386
crossref_primary_10_1002_ehf2_12540
crossref_primary_10_3389_fphys_2021_729713
crossref_primary_10_1002_ehf2_12583
Cites_doi 10.1093/eurheartj/eht302
10.1245/s10434-006-9179-5
10.1007/s13539-013-0116-8
10.1001/archinte.160.6.861
10.1152/physrev.00016.2008
10.1007/s11936-014-0296-3
10.1016/j.ijcard.2013.04.150
10.1016/j.clnu.2008.06.013
10.1007/s13539-012-0067-5
10.1097/01.mco.0000078984.18774.02
10.1159/000356760
10.1007/978-88-470-0552-5_54
10.1016/j.cardfail.2008.06.063
10.1054/bjoc.2001.1696
10.1158/1078-0432.CCR-06-2307
10.1016/j.ajpath.2010.12.009
10.1152/ajpheart.00720.2015
10.1007/s13539-012-0096-0
10.1161/01.CIR.0000133187.74800.B9
10.1016/j.cell.2010.07.011
10.1038/nrc927
10.1007/s13539-014-0157-7
10.1038/nrc3829
10.1016/j.jacc.2014.07.948
10.1517/14728210903369351
10.1200/jco.2014.32.15_suppl.10021
10.1093/jnci/djp440
10.1007/s13539-014-0137-y
10.1016/S1470-2045(10)70218-7
10.1016/j.lfs.2010.12.010
10.1016/j.cardfail.2010.06.041
10.1007/s13539-014-0153-y
10.1517/13543784.16.8.1241
10.1093/annonc/mdp605
ContentType Journal Article
Copyright 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
2017. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
– notice: 2017. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1002/ehf2.12184
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
ProQuest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest - Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 7X7
  name: ProQuest Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Cardiac wasting in cancer
EISSN 2055-5822
EndPage 467
ExternalDocumentID PMC5695173
29154433
10_1002_ehf2_12184
EHF212184
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: German Academic Exchange Service (DAAD)
  funderid: A/08/76145
– fundername: German Academic Exchange Service (DAAD)
  grantid: A/08/76145
GroupedDBID 0R~
1OC
24P
53G
5VS
7X7
8FI
8FJ
AAMMB
ABUWG
ACCMX
ACXQS
ADBBV
ADKYN
ADZMN
AEFGJ
AFKRA
AGXDD
AIDQK
AIDYY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
DIK
EBS
EJD
EMOBN
FYUFA
GODZA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
INH
ITC
KQ8
M~E
OK1
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PUEGO
RPM
UKHRP
WIN
AAHHS
AAYXX
ACCFJ
ADZOD
AEEZP
AEQDE
AIWBW
AJBDE
ALIPV
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c4764-33d4c9a21a29ae2aa0cec5082288f3eb1a77b4ed7e8411740c4c70d8325b4aa53
IEDL.DBID 24P
ISSN 2055-5822
IngestDate Thu Aug 21 18:10:32 EDT 2025
Fri Sep 05 12:58:29 EDT 2025
Wed Aug 13 09:14:33 EDT 2025
Thu Apr 03 07:01:41 EDT 2025
Thu Apr 24 23:12:37 EDT 2025
Tue Jul 01 01:34:49 EDT 2025
Sun Sep 21 06:11:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Cancer cachexia
Heart weight
Cardiac function
Weight loss
Language English
License Attribution-NonCommercial
2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4764-33d4c9a21a29ae2aa0cec5082288f3eb1a77b4ed7e8411740c4c70d8325b4aa53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to the manuscript.
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fehf2.12184
PMID 29154433
PQID 2290182247
PQPubID 4368362
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5695173
proquest_miscellaneous_1966448039
proquest_journals_2290182247
pubmed_primary_29154433
crossref_citationtrail_10_1002_ehf2_12184
crossref_primary_10_1002_ehf2_12184
wiley_primary_10_1002_ehf2_12184_EHF212184
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2017
PublicationDateYYYYMMDD 2017-11-01
PublicationDate_xml – month: 11
  year: 2017
  text: November 2017
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
– name: Hoboken
PublicationTitle ESC Heart Failure
PublicationTitleAlternate ESC Heart Fail
PublicationYear 2017
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 2009; 89
2010; 16
2013; 4
2010; 37
2006; 14
2000; 7
2010; 102
2008; 14
2002; 2
2006
2010; 142
2013; 168
2011; 12
2011; 39
2004; 109
2014; 60
2007; 13
2001; 84
2011; 178
2012; 53
2007; 16
2014; 64
2009; 14
2010; 21
2014; 5
2012; 3
2003; 6
2008; 27
2000; 160
2014; 16
2016; 310
2014; 14
2011; 88
2014; 35
2014; 32
e_1_2_8_28_1
e_1_2_8_24_1
e_1_2_8_25_1
Costelli P (e_1_2_8_10_1) 2003; 6
e_1_2_8_26_1
e_1_2_8_27_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
Dimos AK (e_1_2_8_31_1) 2012; 53
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_17_1
e_1_2_8_18_1
Tian M (e_1_2_8_23_1) 2010; 37
e_1_2_8_39_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
Balloni L (e_1_2_8_29_1) 2000; 7
e_1_2_8_38_1
e_1_2_8_16_1
e_1_2_8_37_1
Tian M (e_1_2_8_22_1) 2011; 39
e_1_2_8_32_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – volume: 88
  start-page: 406
  year: 2011
  end-page: 410
  article-title: Myocardial dysfunction in an animal model of cancer cachexia
  publication-title: Life Sci
– volume: 89
  start-page: 381
  year: 2009
  end-page: 410
  article-title: Mechanisms of cancer cachexia
  publication-title: Physiol Rev
– volume: 37
  start-page: 347
  year: 2010
  end-page: 353
  article-title: Cardiac alterations in cancer‐induced cachexia in mice
  publication-title: Int J Oncol
– volume: 16
  start-page: 296
  year: 2014
  article-title: Cardiac complications of chemotherapy: role of imaging
  publication-title: Curr Treat Options Cardiovasc Med
– volume: 142
  start-page: 531
  year: 2010
  end-page: 543
  article-title: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival
  publication-title: Cell
– volume: 21
  start-page: 1594
  year: 2010
  end-page: 1598
  article-title: Low body mass index and sarcopenia associated with dose‐limiting toxicity of sorafenib in patients with renal cell carcinoma
  publication-title: Ann Oncol
– volume: 4
  start-page: 287
  year: 2013
  end-page: 293
  article-title: Disruption of pro‐oxidant and antioxidant systems with elevated expression of the ubiquitin proteosome system in the cachectic heart muscle of nude mice
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 14
  start-page: S18
  year: 2008
  article-title: Experimental cancer cachexia severely impairs heart function
  publication-title: J Cardiac Fail
– volume: 35
  start-page: 932
  year: 2014
  end-page: 941
  article-title: Prevention of liver cancer cachexia‐induced cardiac wasting and heart failure
  publication-title: Eur Heart J
– volume: 53
  start-page: 127
  year: 2012
  end-page: 136
  article-title: “First, do no harm”: chemotherapy or healthy heart?
  publication-title: Hellenic J Cardiol
– volume: 102
  start-page: 14
  year: 2010
  end-page: 25
  article-title: Cardiotoxicity of anticancer drugs: the need for cardio‐oncology and cardio‐oncological prevention
  publication-title: J Natl Cancer Inst
– volume: 178
  start-page: 1059
  year: 2011
  end-page: 1068
  article-title: NF‐kB inhibition protects against tumor‐induced cardiac atrophy in vivo
  publication-title: Am J Pathol
– volume: 12
  start-page: 489
  year: 2011
  end-page: 495
  article-title: Definition and classification of cancer cachexia: an international consensus
  publication-title: Lancet Oncol
– volume: 168
  start-page: 3412
  year: 2013
  end-page: 3418
  article-title: Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia
  publication-title: Int J Cardiol
– volume: 2
  start-page: 862
  year: 2002
  end-page: 871
  article-title: Cachexia in cancer patients
  publication-title: Nat Rev Cancer
– volume: 39
  start-page: 1321
  year: 2011
  end-page: 1326
  article-title: Evidence for cardiac atrophic remodeling in cancer‐induced cachexia in mice
  publication-title: Int J Oncol
– volume: 14
  start-page: 754
  year: 2014
  end-page: 762
  article-title: Cancer cachexia: understanding the molecular basis
  publication-title: Nat Rev Cancer
– volume: 6
  start-page: 407
  year: 2003
  end-page: 412
  article-title: Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP‐ubiquitin dependent proteolysis
  publication-title: Curr Opin Clin Nutr Metab Care
– volume: 109
  start-page: 3122
  year: 2004
  end-page: 3131
  article-title: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management
  publication-title: Circulation
– volume: 310
  start-page: H466
  year: 2016
  end-page: H477
  article-title: The pathogenesis and treatment of cardiac atrophy in cancer cachexia
  publication-title: Am J Physiol Heart Circ Physiol
– volume: 16
  start-page: 1241
  year: 2007
  end-page: 1253
  article-title: Novel treatments for cancer cachexia
  publication-title: Expert Opin Investig Drugs
– volume: 84
  start-page: 946
  year: 2001
  end-page: 950
  article-title: Activation of Ca ‐dependent proteolysis in skeletal muscle and heart in cancer cachexia
  publication-title: Br J Cancer
– volume: 5
  start-page: 95
  year: 2014
  end-page: 104
  article-title: Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 64
  start-page: 1310
  year: 2014
  end-page: 1319
  article-title: Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer
  publication-title: J Am Coll Cardiol
– volume: 14
  start-page: 276
  year: 2006
  end-page: 285
  article-title: Cancer cachexia: it's time for more clinical trials
  publication-title: Annals of Surgical Oncology
– start-page: 563
  year: 2006
  end-page: 579
– volume: 3
  start-page: 73
  year: 2012
  end-page: 76
  article-title: Are there any benefits of exercise training in cancer cachexia?
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 4
  start-page: 111
  year: 2013
  end-page: 124
  article-title: Cancer cachexia prevention via physical exercise: molecular mechanisms
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 27
  start-page: 793
  year: 2008
  end-page: 799
  article-title: Cachexia: a new definition
  publication-title: Clin Nutr
– volume: 32
  start-page: 10021
  year: 2014
  article-title: Hearts too small for body size after doxorubicin for childhood ALL: Grinch syndrome
  publication-title: J Clin Oncol
– volume: 16
  start-page: S12
  year: 2010
  article-title: Cancer cachexia therapy: a matter of helping the heart?
  publication-title: J Cardiac Fail
– volume: 5
  start-page: 193
  year: 2014
  end-page: 198
  article-title: Muscle wasting: an overview of recent developments in basic research
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 14
  start-page: 619
  year: 2009
  end-page: 632
  article-title: Update on emerging drugs for cancer cachexia
  publication-title: Expert Opin Emerg Drugs
– volume: 160
  start-page: 861
  year: 2000
  end-page: 868
  article-title: Clinical survival predictors in patients with advanced cancer
  publication-title: Arch Intern Med
– volume: 5
  start-page: 315
  year: 2014
  end-page: 320
  article-title: Formoterol in the treatment of experimental cancer cachexia: effects on heart function
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 13
  start-page: 1356
  year: 2007
  end-page: 1361
  article-title: Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome
  publication-title: Clin Cancer Res
– volume: 60
  start-page: 294
  year: 2014
  end-page: 305
  article-title: Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options—a mini‐review
  publication-title: Gerontology
– volume: 7
  start-page: 887
  year: 2000
  end-page: 890
  article-title: Left ventricular function in colon cancer patients receiving adjuvant fluoro‐folate chemotherapy: an echocardiographic study
  publication-title: Oncol Rep
– ident: e_1_2_8_21_1
  doi: 10.1093/eurheartj/eht302
– ident: e_1_2_8_2_1
  doi: 10.1245/s10434-006-9179-5
– ident: e_1_2_8_15_1
  doi: 10.1007/s13539-013-0116-8
– ident: e_1_2_8_13_1
  doi: 10.1001/archinte.160.6.861
– ident: e_1_2_8_9_1
  doi: 10.1152/physrev.00016.2008
– ident: e_1_2_8_27_1
  doi: 10.1007/s11936-014-0296-3
– ident: e_1_2_8_37_1
  doi: 10.1016/j.ijcard.2013.04.150
– ident: e_1_2_8_18_1
  doi: 10.1016/j.clnu.2008.06.013
– ident: e_1_2_8_39_1
  doi: 10.1007/s13539-012-0067-5
– volume: 6
  start-page: 407
  year: 2003
  ident: e_1_2_8_10_1
  article-title: Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP‐ubiquitin dependent proteolysis
  publication-title: Curr Opin Clin Nutr Metab Care
  doi: 10.1097/01.mco.0000078984.18774.02
– ident: e_1_2_8_14_1
  doi: 10.1159/000356760
– ident: e_1_2_8_17_1
  doi: 10.1007/978-88-470-0552-5_54
– ident: e_1_2_8_20_1
  doi: 10.1016/j.cardfail.2008.06.063
– ident: e_1_2_8_11_1
  doi: 10.1054/bjoc.2001.1696
– volume: 39
  start-page: 1321
  year: 2011
  ident: e_1_2_8_22_1
  article-title: Evidence for cardiac atrophic remodeling in cancer‐induced cachexia in mice
  publication-title: Int J Oncol
– volume: 53
  start-page: 127
  year: 2012
  ident: e_1_2_8_31_1
  article-title: “First, do no harm”: chemotherapy or healthy heart?
  publication-title: Hellenic J Cardiol
– ident: e_1_2_8_8_1
  doi: 10.1158/1078-0432.CCR-06-2307
– ident: e_1_2_8_35_1
  doi: 10.1016/j.ajpath.2010.12.009
– ident: e_1_2_8_38_1
  doi: 10.1152/ajpheart.00720.2015
– volume: 7
  start-page: 887
  year: 2000
  ident: e_1_2_8_29_1
  article-title: Left ventricular function in colon cancer patients receiving adjuvant fluoro‐folate chemotherapy: an echocardiographic study
  publication-title: Oncol Rep
– ident: e_1_2_8_6_1
  doi: 10.1007/s13539-012-0096-0
– ident: e_1_2_8_28_1
  doi: 10.1161/01.CIR.0000133187.74800.B9
– ident: e_1_2_8_34_1
  doi: 10.1016/j.cell.2010.07.011
– ident: e_1_2_8_4_1
  doi: 10.1038/nrc927
– ident: e_1_2_8_16_1
  doi: 10.1007/s13539-014-0157-7
– ident: e_1_2_8_3_1
  doi: 10.1038/nrc3829
– ident: e_1_2_8_25_1
  doi: 10.1016/j.jacc.2014.07.948
– volume: 37
  start-page: 347
  year: 2010
  ident: e_1_2_8_23_1
  article-title: Cardiac alterations in cancer‐induced cachexia in mice
  publication-title: Int J Oncol
– ident: e_1_2_8_7_1
  doi: 10.1517/14728210903369351
– ident: e_1_2_8_33_1
  doi: 10.1200/jco.2014.32.15_suppl.10021
– ident: e_1_2_8_30_1
  doi: 10.1093/jnci/djp440
– ident: e_1_2_8_26_1
  doi: 10.1007/s13539-014-0137-y
– ident: e_1_2_8_5_1
  doi: 10.1016/S1470-2045(10)70218-7
– ident: e_1_2_8_24_1
  doi: 10.1016/j.lfs.2010.12.010
– ident: e_1_2_8_19_1
  doi: 10.1016/j.cardfail.2010.06.041
– ident: e_1_2_8_36_1
  doi: 10.1007/s13539-014-0153-y
– ident: e_1_2_8_12_1
  doi: 10.1517/13543784.16.8.1241
– ident: e_1_2_8_32_1
  doi: 10.1093/annonc/mdp605
SSID ssj0001561524
Score 2.3419485
Snippet Aims Cachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with...
Cachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with...
AimsCachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 458
SubjectTerms Adult
Aged
Aged, 80 and over
Anorexia
Body Mass Index
Cachexia - complications
Cachexia - epidemiology
Cachexia - metabolism
Cancer cachexia
Cancer therapies
Cardiac function
Chemotherapy
Drug therapy
Family medical history
Female
Fitness training programs
Germany - epidemiology
Heart
Heart Failure - epidemiology
Heart Failure - etiology
Heart Failure - metabolism
Heart weight
Humans
Laboratories
Lung cancer
Male
Medical prognosis
Middle Aged
Morbidity - trends
Muscle, Skeletal - metabolism
Muscle, Skeletal - physiopathology
Musculoskeletal system
Myocardium - metabolism
Neoplasms - complications
Neoplasms - epidemiology
Original
Original s
Pancreatic cancer
Pathology
Proteins
Pulmonary arteries
Quality of life
Retrospective Studies
Studies
Survival Rate - trends
Tumor necrosis factor-TNF
Weight loss
Young Adult
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEB58gHgR39YXFb0oFLtp2rReRMRlEfSksLcyTVJc0O5qXfTnO5PtVhfFUwudvmaSyZfJ5BuAkyQrCxObNEisKQNpShUURZFwrReNhJALdGU67-6T3qO87cf9JuBWN2mVU5_oHLUZao6RnzMveYdTHtXl6DXgqlG8utqU0JiHxQ4hES7doPrqO8ZC4CAWsmUlFef2qRRMqJDK2XHoF7j8nSP5E7u6wae7CisNavSvJmZegzlbrcPSXbMuvgEX187Q2n8Z1yTgf2DN6cz-oPIH7Y6r2uegq6_Zzm90IHN9DnATHrs3D9e9oKmKEGipEhlEkZE6Q9FBkaEViKG2Ombi9jQtI3K9qFQhrVE2lR2ab4RaahUa6rlxIRHjaAsWqmFld8AvDYb0FIGJMZKkMxuitAQgjESVZsqD06mOct1QhnPliud8QnYsctZn7vTpwXErO5oQZfwptT9Vdd50ljr_Nq0HR-1laua8doGVHY7rnBwFzyTDKPNge2KZ9jUiY0qhKPJAzdisFWAK7dkr1eDJUWnHCSFMRXeeOev-8-X5Ta8r3Nnu__-wB8uCh363X3EfFt7fxvaAgMt7ceha5xcDl-0g
  priority: 102
  providerName: ProQuest
Title Cardiac muscle wasting in individuals with cancer cachexia
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fehf2.12184
https://www.ncbi.nlm.nih.gov/pubmed/29154433
https://www.proquest.com/docview/2290182247
https://www.proquest.com/docview/1966448039
https://pubmed.ncbi.nlm.nih.gov/PMC5695173
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swED_6AaMvY133ka0NHu3LBqaOLFl26UtXEsKgpYwW8mZOH6aBzh11w_bn7052nIWWwV5sg86WudNJP52k3wEcZUVlnHJ5nHlXxdJVOjbGZJzrxSIhZIMhTefFZTa9kd9marYBp8uzMC0_RB9wY88I_TU7OJrmeEUa6m8rwdwIudyEbUL1KbdvIa9WERaCBipktRWJUrGiobDnJxXHq9fXR6QnMPPpbsm_UWwYhiav4GWHH6Oz1uC7sOHr1_Diolsh34OT82ByG_1YNCQQ_cKGNzZH8zqa92evmojDr5Fliz_QjQz3e45v4GYyvj6fxl1-hNhKnck4TZ20BYoRigK9QEyst4op3PO8SqkTRq2N9E77XI5o5pFYaXXiyIeVkYgqfQtb9X3t30NUOUzoKwIz5yRJFz5B6QlKOIk6L_QAPi91VNqOPJxzWNyVLe2xKFmfZdDnAA572Z8tZcazUvtLVZed2zQlk8-PeF8rVfipL6YGz6sYWPv7RVNSl8FzyiQtBvCutUxfjSiYXChNB6DXbNYLMJn2ekk9vw2k2iojrKnpzS_Buv_483I8nYjw9OF_hD_CjmBIEM4x7sPW48PCHxCgeTTD0G7pqmd6CNtfx5dX34chOPAH9Xjy-A
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9NnQS8IMZnYBtGwANI0VLHiROkCY3RqmNrhdAm7c1zbEerBOlYVg3-Of427twkoxra254SKZevu7P989n3O4A3aV4WNrFZmDpbhsKWMiyKIqVaL0YjQi60L9M5nqSjI_HlODlegT9tLgxtq2z7RN9R25mhGPkW8ZL3acuj_Hj2M6SqUbS62pbQ0E1pBbvtKcaaxI599_sSp3D19t5ntPdbzoeDw91R2FQZCI2QqQjj2AqTa97XPNeOax0ZZxIiQs-yMsauTEtZCGely0Qf8XtkhJGRxZaQFEJrqhqBQ8CqoABKD1Y_DSZfv11FeRCeJFx0vKh8y52WnCgdMrE8El6Dt9d3af6Lnv3wN3wA9xvcynYWjrYGK656CHfGzcr8I_iw613NsB_zGgXYpa5pQzWbVmza5XzVjMK-zJCnneMBHebXVD-Go1vR2BPoVbPKPQNWWh3hU7hOrRUonbtIC4cQxgots1wG8K7VkTINaTnVzviuFnTLXJE-lddnAK872bMFVcd_pdZbVaumudbqyrkCeNVdxoZGqye6crN5rbCrorlsFOcBPF1YpnsNz4nUKI4DkEs26wSIxHv5SjU99WTeSYoYV-Kd7711b_hyNRgNuT97fvM_vIS7o8PxgTrYm-y_gHucgIjPnlyH3sX53G0gjLooNhtfZXBy283jLxOQMCE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dS9xAEB9EQfpSqv1K1XZL24cWwuU2m2xSEGn1jrPWQ0oF3-Jmd4MHbU6Nh-2_2L-qM3ub2MPim08JZPI1O7P7292Z3wC8TfOqNInJwtSaKhSmkmFZlinVetEKEXKpXJnOw3E6OhZfTpKTJfjT5sJQWGXbJ7qO2kw1rZH3iJe8TyGPslf5sIijveHO-UVIFaRop7Utp6F8mQWz7ejGfJLHgf19jdO5Znt_D9v-HefDwffdUegrDoRayFSEcWyEzhXvK54ry5WKtNUJkaJnWRVjt6akLIU10maij1g-0kLLyKBXJKVQiipI4HCwInHUx4ngyufB-OjbzYoPQpWEi44jlffsWcWJ3iETi6PiLah7O2LzXyTthsLhI3joMSz7NDe6NViy9TqsHvpd-sfwcdeZnWY_Zw0KsGvVUHA1m9Rs0uV_NYyWgJkmq7vEAxrPr4l6Asf3orGnsFxPa_scWGVUhE_hKjVGoHRuIyUswhkjlMxyGcD7VkeF9gTmVEfjRzGnXuYF6bNw-gzgTSd7Pqft-K_UZqvqwrtuU9wYWgCvu8vodLSTomo7nTUFdls0r43iPIBn85bpXsNzIjiK4wDkQpt1AkTovXilnpw5Yu8kRbwr8c4PrnXv-PJiMBpyd_bi7n94BavoJsXX_fHBBjzghElcIuUmLF9dzuwWIqqr8qU3VQan9-0dfwFWHjRl
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiac+muscle+wasting+in+individuals+with+cancer+cachexia&rft.jtitle=ESC+Heart+Failure&rft.au=Barkhudaryan%2C+Anush&rft.au=Scherbakov%2C+Nadja&rft.au=Springer%2C+Jochen&rft.au=Doehner%2C+Wolfram&rft.date=2017-11-01&rft.pub=John+Wiley+and+Sons+Inc&rft.eissn=2055-5822&rft.volume=4&rft.issue=4&rft.spage=458&rft.epage=467&rft_id=info:doi/10.1002%2Fehf2.12184&rft_id=info%3Apmid%2F29154433&rft.externalDocID=PMC5695173
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2055-5822&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2055-5822&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2055-5822&client=summon